AEterna Zentaris and AVI BioPharma Maintain Steady Pipelines
September 06 2011 - 8:16AM
Marketwired
The importance of maintaining a steady pipeline of drugs to market
is having varied effects on the biotechnology industry. Analysis by
the professional services firm BDO argues that larger
Pharmaceutical firms are increasing reliance on biotech companies
to fill its pipeline, which has been a net positive for small
biotech companies. The Bedford Report examines the outlook for
companies in the biotechnology industry and provides investment
research on AEterna Zentaris, Inc. (NASDAQ: AEZS) (TSX: AEZ) and
AVI BioPharma, Inc. (NASDAQ: AVII). Access to the full company
reports can be found at:
www.bedfordreport.com/AEZS
www.bedfordreport.com/AVII
While the positive fundamentals are there, last month biotech
stocks suffered from what MarketWatch's Val Brickates Kennedy calls
the "Dendreon Effect." The article reports that biotech companies
whose stocks have taken heavy hits include those that are at early
stages of marketing new treatments.
"Pretty much every company that had just launched a product or
was about to launch a product got crushed," Leerink Swann analyst
Howard Liang explains.
The Bedford Report releases market research on the Biotechnology
Industry so investors can stay ahead of the crowd and make the best
investment decisions to maximize their returns. Take a few minutes
to register with us free at www.bedfordreport.com and get exclusive
access to our numerous analyst reports and industry
newsletters.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, multiple myeloma, endometrial,
ovarian, prostate and bladder cancer. Recently the company reported
positive late-stage results for its product used to diagnose adult
growth hormone deficiency.
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. For the second quarter of
2011 AVI reported an operating loss of $10.1 million compared with
an operating loss of $7.7 million in the second quarter of
2010.
The Bedford Report provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024